Exercise-Benchmark CD28 Endpoint for Immune-Aging Drug Trials

A standardized flow-cytometry endpoint service for pharma and CROs running early-phase trials of immune-aging therapies, reporting whether a drug restores elderly patients' CD28+ T-helper and Th1 cells to the level achievable by 6 months of moderate exercise — the quantified no-drug benchmark.